Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry Seven-Year Interim Results.
Hermine I BrunnerKabita NandaMary TothIvan FoeldvariJohn BohnsackDiana MilojevicC Egla RabinovichDaniel J KingsburyKatherine MarzanElizabeth ChalomGerd HorneffRolf-Michael KuesterJason A DareMaria TrachanaLawrence K JungJudyann OlsonKirsten MindenPierre QuartierMareike BereswillJasmina KalabicHartmut KupperDaniel J LovellAlberto MartiniNicolino Rupertonull nullPublished in: Arthritis care & research (2020)
The STRIVE registry 7-year interim results support the idea that ADA ± MTX is well tolerated by most children. Registry median ADA exposure was 2.47 (interquartile range 1.0-3.6) years, with 42% of patients continuing ADA at the 7-year cutoff date.